



(51) International Patent Classification:

C07D 475/04 (2006.01) A61K 31/4985 (2006.01)
C07D 475/12 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2010/061551

(22) International Filing Date:

21 December 2010 (21.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/289,980 23 December 2009 (23.12.2009) US
61/404,797 8 October 2010 (08.10.2010) US

(71) Applicant (for all designated States except US): **ELAN PHARMACEUTICALS, INC** [US/US]; 800 Gateway Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GALEMMO, Robert, A., Jr.** [US/US]; 24 Whale Ship Plaza, San Francisco, CA 94111 (US). **ARTIS, Dean Richard** [US/US]; 50 Arlmont Drive, Kensington, CA 94707 (US). **YE, Xiocong Michael** [US/US]; 3360 Ramona Street, Palo Alto, CA 94306 (US). **AUBELE, Danielle, L.** [US/US]; 1425 Bellevue Avenue, #3, Burlin ame, CA 94010 (US). **TRUONG, Anh, P.** [US/US]; 1031 Chula Vista Avenue, Burlingame, CA 94010 (US). **BOWERS, Simeon** [US/US]; 3252 Birdsall Avenue, Oakland, CA 94619 (US). **HOM, Roy, K.** [US/US]; 201 Laguna Street #14, San Francisco, CA 94102 (US). **ZHU, Yong-Liang** [US/US]; 43215 Fresco Terrace, Fremont CA 94539 (US).

NEITZ, R., Jeffrey [US/US]; 2658 23rd Avenue, San Francisco, CA 94116 (US). **SEALY, Jennifer** [US/US]; 1683 Miami Court, Oakland, CA 94602 (US). **ADLER, Marc** [US/US]; 110 El Toyonal Road, Orinda CA 94563 (US). **BEROZA, Paul** [US/US]; 1011 Muir Way, Belmont, CA 94002 (US). **ANDERSON, John, P.** [US/US]; 1323-A Lyon Street, San Francisco, CA 941 15 (US).

(74) Agent: **BURGY, Adriana, L.**; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, DC 20001-4413 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE



(I)

(57) Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, E¹, E², R¹, R², R³ and R⁴ are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.



-
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- Published:**
- *with international search report (Art. 21(3))*